Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target.

Hereditas · 2025 · PMC11931869 · PMID 40128844

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The analysis of OS revealed that patients with CSNK1A1 mutations showed a trend toward better survival probabilities compared to those without mutations; however, the difference was not statistically significant ( P = 0.211) (Fig. 3 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.